Rarecells Diagnostics SAS
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor Cells, for the diagnosis of multiple cancer types and personalized therapeutic. Develop breakthrough noninvasive tests for earlier cancer diagnosis based on disruptive morpho-molecular rare cells technology.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Monitoring
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2011
Welcome
The ISET© technology is able to extract a single Circulating Tumor Cell (CTC) from 10 ml of blood (thus mixed with approx. 100 M. of leucocytes and 50 B. of erythrocytes) keeping CTCs intact and ready for morpho-molecular analyses, providing unparalleled sensitivity and specificity.
ISET© also extracts from blood, without loss, circulating giant cells and tumor cell clusters (micro-emboli).
Rarecells partners with the most prestigious US academic institutions to bring to the market the ISET© non-invasive tests, contributing to the eradication of cancer.
About Us
Worldwide, about 18.1 million new cancers were diagnosed and 9.6 million people died of the disease. Therefore, finding an effective, non-invasive way to diagnose cancers accurately and earlier has the potential to save millions of lives each year.
The global liquid biopsy market was estimated at EUR 8.2 billion in 2017 with an expected growth to EUR 24.9 billion by 2023.
At Rarecells Diagnostics, we focused on the most critical healthcare unmet needs : the early detection of cancers. Delivering to caregivers the unique possibility to identify the presence of circulating cancer cells up to 4-5 years in advance of traditional imaging techniques and/or clinical symptoms.
The company was founded in 2011 by Patrizia Paterlini-Bréchot, an Italian-French Woman, Onco-Hematologist, Prof. of Cellular and Molecular Biology at the University Paris Descartes (France) and inventor of the ISET® technology.
Rarecells Diagnostics is a spin-off of the French Public Institutions : Université Paris Descartes, INSERM (Institut National de la Santé et de la Recherche Médicale) and AP-HP (Assistance Publique- Hôpitaux de Paris) which own the ISET® patents. Rarecells Diagnostics has the exclusive licenses of the ISET® patents.
Mission
Disrupt today’s cancer patient care toward personalized medicine and earlier detection of the disease for the benefit of people’s life, through an increased understanding of circulating tumor cells biology and the delivery of non-invasive powerful diagnostic tools based on rare circulating information in the blood.